Skip Navigation

This Article
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Duijkers, I.J.M.
Right arrow Articles by Vemer, H.M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Duijkers, I.J.M.
Right arrow Articles by Vemer, H.M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 12, No. 11, pp. 2379-2384, 1997
© 1997 European Society of Human Reproduction and Embryology

Pharmacodynamics and pharmacokinetics after repeated subcutaneous administration of three gonadotrophin preparations

I.J.M. Duijkers1,2,4, C. Klipping1, T.M.T. Mulders3, H.J. Out3, H.J.T. Coelingh Bennink3 and H.M. Vemer2,3

1 Dinox BV Medical Investigations Nijmegen 2 Department of Obstetrics and Gynaecology, University Hospital Nijmegen St. Radboud Nijmegen 3 NV Organon, Oss The Netherlands

Correspondence: 4To whom correspondence should be addressed at: Dinox BV, Medical Investigations, Groenewoudesweg 317, 6524 Tx Nijmegen, The Netherlands

Recently, several new urinary gonadotrophin preparations have been developed, containing less luteinizing hormone (LH) activity than human menopausal gonadotrophin. Normegon is a gonadotrophin preparation with a follicle stimulating hormone (FSH)/LH ratio of 3:1; Follegon and Metrodin-HP are purified FSH preparations. The aim of the present randomized study was to compare pharmacodynamics, -kinetics and local tolerance of these preparations after repeated s.c. administration. Thirty-six healthy female subjects were treated with Lyndiol contraceptive pills for 5 weeks to suppress endogenous gonadotrophin concentrations. After 3 weeks of Lyndiol treatment, 150 IU of Normegon, Follegon or Metrodin HP were administered once daily, s.c. for 7 days. Blood samples were collected once daily during the fourth and fifth weeks of the study and assayed for FSH and oestradiol. After the last gonadotrophin injection, blood samples were collected more frequently to determine pharmacokinetic parameters of FSH. During the fourth and fifth study weeks, daily ultrasound measurements of follicular growth were performed. Endogenous FSH and LH values were extremely suppressed during Lyndiol treatment. Serum FSH values showed similar patterns in the three groups. The maximum FSH concentration was reached 9–11 h post-injection, the terminal half-life was 43–47 h. The preparations were bioequivalent with respect to FSH immunoreactivity. The number of follicles tended to be larger after Normegon than after Follegon and Metrodin HP treatment, though this was not statistically significant. Serum oestradiol concentrations were significantly higher after Normegon treatment. In general, s.c injections were well tolerated. In conclusion, the three preparations were bioequivalent with respect to FSH immunoreactivity. Nevertheless, the biological activity of Normegon tended to be higher than that of Follegon and Metrodin HP in Lyndiol-suppressed women.

Key words: FSH/gonadotrophin/pharmacodynamics/pharmacokinetics/subcutaneous

Submitted on April 11, 1997; accepted on July 28, 1997.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Biol. Reprod.Home page
J. Uma, P. Muraly, S. Verma-Kumar, and R. Medhamurthy
Determination of Onset of Apoptosis in Granulosa Cells of the Preovulatory Follicles in the Bonnet Monkey (Macaca radiata): Correlation with Mitogen-Activated Protein Kinase Activities
Biol Reprod, October 1, 2003; 69(4): 1379 - 1387.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
P.E. Egbase, M. Al Sharhan, and J.G. Grudzinskas
'Early coasting' in patients with polycystic ovarian syndrome is consistent with good clinical outcome
Hum. Reprod., May 1, 2002; 17(5): 1212 - 1216.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
G. Voortman, J. van de Post, R. C. Schoemaker, and J. M.A. van Gerven
Bioequivalence of subcutaneous injections of recombinant human follicle stimulating hormone (Puregon(R)) by Pen-injector and syringe
Hum. Reprod., July 1, 1999; 14(7): 1698 - 1702.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.